BR112015011748A2 - terapia de combinação com volasertib - Google Patents
terapia de combinação com volasertibInfo
- Publication number
- BR112015011748A2 BR112015011748A2 BR112015011748A BR112015011748A BR112015011748A2 BR 112015011748 A2 BR112015011748 A2 BR 112015011748A2 BR 112015011748 A BR112015011748 A BR 112015011748A BR 112015011748 A BR112015011748 A BR 112015011748A BR 112015011748 A2 BR112015011748 A2 BR 112015011748A2
- Authority
- BR
- Brazil
- Prior art keywords
- volasertib
- combination therapy
- combination
- gcsf
- fludarabine
- Prior art date
Links
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 title abstract 4
- 229950003081 volasertib Drugs 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title abstract 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 2
- 229960000684 cytarabine Drugs 0.000 abstract 2
- 229960000390 fludarabine Drugs 0.000 abstract 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 abstract 2
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 229940052372 daunorubicin citrate liposome Drugs 0.000 abstract 1
- 210000003714 granulocyte Anatomy 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195162 | 2012-11-30 | ||
| PCT/EP2013/074862 WO2014083058A1 (en) | 2012-11-30 | 2013-11-27 | Combination therapy with volasertib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015011748A2 true BR112015011748A2 (pt) | 2017-07-11 |
Family
ID=47325907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015011748A BR112015011748A2 (pt) | 2012-11-30 | 2013-11-27 | terapia de combinação com volasertib |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140154304A1 (https=) |
| EP (1) | EP2925343A1 (https=) |
| JP (1) | JP2016501208A (https=) |
| KR (1) | KR20150090091A (https=) |
| CN (1) | CN104812400A (https=) |
| AU (1) | AU2013351180A1 (https=) |
| BR (1) | BR112015011748A2 (https=) |
| CA (1) | CA2889787A1 (https=) |
| CL (1) | CL2015001258A1 (https=) |
| EA (1) | EA201500579A1 (https=) |
| IL (1) | IL238174A0 (https=) |
| IN (1) | IN2015DN03075A (https=) |
| MX (1) | MX2015006592A (https=) |
| PH (1) | PH12015501113A1 (https=) |
| WO (1) | WO2014083058A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867831B2 (en) * | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| CN104306336B (zh) * | 2014-11-18 | 2016-08-24 | 河北天成药业股份有限公司 | 枸橼酸柔红霉素脂质体注射液的制备工艺 |
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| WO2021242859A1 (en) * | 2020-05-27 | 2021-12-02 | Duke University | Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy |
| CN116785296B (zh) * | 2023-06-06 | 2025-09-05 | 河北渤腾医药技术有限公司 | 一种plk1的抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0318145A (pt) | 2003-02-26 | 2006-02-21 | Boehringer Ingelheim Pharma | dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| CA2673040C (en) * | 2006-12-20 | 2016-02-02 | Universitaetsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| EP4046640A1 (en) * | 2007-02-16 | 2022-08-24 | Rotalec IP Holdings LLC | Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
-
2013
- 2013-11-25 US US14/088,948 patent/US20140154304A1/en not_active Abandoned
- 2013-11-27 EA EA201500579A patent/EA201500579A1/ru unknown
- 2013-11-27 WO PCT/EP2013/074862 patent/WO2014083058A1/en not_active Ceased
- 2013-11-27 JP JP2015544453A patent/JP2016501208A/ja active Pending
- 2013-11-27 KR KR1020157014213A patent/KR20150090091A/ko not_active Withdrawn
- 2013-11-27 MX MX2015006592A patent/MX2015006592A/es unknown
- 2013-11-27 CA CA2889787A patent/CA2889787A1/en not_active Abandoned
- 2013-11-27 EP EP13795533.2A patent/EP2925343A1/en not_active Withdrawn
- 2013-11-27 AU AU2013351180A patent/AU2013351180A1/en not_active Abandoned
- 2013-11-27 BR BR112015011748A patent/BR112015011748A2/pt not_active IP Right Cessation
- 2013-11-27 CN CN201380062203.7A patent/CN104812400A/zh active Pending
-
2015
- 2015-04-12 IL IL238174A patent/IL238174A0/en unknown
- 2015-04-13 IN IN3075DEN2015 patent/IN2015DN03075A/en unknown
- 2015-05-11 CL CL2015001258A patent/CL2015001258A1/es unknown
- 2015-05-20 PH PH12015501113A patent/PH12015501113A1/en unknown
-
2017
- 2017-03-03 US US15/448,660 patent/US20170173023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013351180A1 (en) | 2015-04-30 |
| JP2016501208A (ja) | 2016-01-18 |
| EP2925343A1 (en) | 2015-10-07 |
| WO2014083058A1 (en) | 2014-06-05 |
| CA2889787A1 (en) | 2014-06-05 |
| MX2015006592A (es) | 2015-08-05 |
| EA201500579A1 (ru) | 2015-12-30 |
| CL2015001258A1 (es) | 2015-10-02 |
| IL238174A0 (en) | 2015-05-31 |
| IN2015DN03075A (https=) | 2015-10-02 |
| US20170173023A1 (en) | 2017-06-22 |
| US20140154304A1 (en) | 2014-06-05 |
| KR20150090091A (ko) | 2015-08-05 |
| CN104812400A (zh) | 2015-07-29 |
| PH12015501113A1 (en) | 2015-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013000446A2 (pt) | composição nutricional para a estimulação de síntese de proteína muscular | |
| CY1116160T1 (el) | Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
| BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
| MY153408A (en) | Novel methods | |
| SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
| PT2139483E (pt) | Terapias de combinação que compreendem um inibidor de quinoxalina de pi3k-alfa para utilizar no tratamento de cancro | |
| BR112012022801B8 (pt) | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer | |
| BR112015011748A2 (pt) | terapia de combinação com volasertib | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BRPI0923300A2 (pt) | "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas" | |
| CL2011000814A1 (es) | Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente. | |
| BR112012010995A2 (pt) | revestimentos e métodos de revestimento de agulhas cirúrgicas | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| AR075982A1 (es) | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112012010994A2 (pt) | revestimentos e métodos de revestimento de agulhas cirúrgicas | |
| BR112014001170A2 (pt) | cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata | |
| BR112013021661A2 (pt) | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MX2009006574A (es) | Tratamiento de cancer de pulmon. | |
| BR112014032169A2 (pt) | tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |